Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 16/20 | 0.53 |
| ▸ | ITGAV | P06756 | 16/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 9/20 | 0.53 |
| ▸ | ITGB5 | P18084 | 7/20 | 0.53 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4714967 | 0.95 | ITGB3 (0.52) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL4761797 | 0.85 | ITGB3 (0.53) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL4715705 | 0.84 | ITGB3 (0.55) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL4760017 | 0.84 | ITGB3 (0.54) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL14221981 | 0.83 | ITGB3 (0.57) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL4718120 | 0.83 | ITGB3 (0.54) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL4762284 | 0.83 | ITGB3 (0.53) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL4760436 | 0.81 | ITGB3 (0.51) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL4761955 | 0.80 | ITGB3 (0.52) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL4791386 | 0.80 | ITGB3 (0.51) | ITGB3ITGAVITGA2BITGB5ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1216230-B1 | FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2008-04-23 | — | — | EP | claimed |
| US-6514964-B1 | Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors | AMGEN INC. | 2003-02-04 | — | — | US | claimed |
| EP-1216230-B1 | FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2008-04-23 | — | — | EP | disclosed |
| EP-1216230-B1 | FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2008-04-23 | — | — | EP | disclosed |
| US-6514964-B1 | Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors | AMGEN INC. | 2003-02-04 | — | — | US | disclosed |